Edition:
United States

Bioverativ Inc (BIVV.OQ)

BIVV.OQ on NASDAQ Stock Exchange Global Select Market

53.47USD
3:59pm EST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$53.47
Open
$53.41
Day's High
$54.04
Day's Low
$53.13
Volume
438,252
Avg. Vol
364,269
52-wk High
$64.40
52-wk Low
$41.21

Chart for

About

Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein],... (more)

Overall

Beta: --
Market Cap(Mil.): $6,375.17
Shares Outstanding(Mil.): 108.18
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Bioverativ’s BIVV009 achieves positive results in Phase 1B CAgD patients

* BIOVERATIV’S INVESTIGATIONAL BIVV009 DEMONSTRATES SAFETY, TOLERABILITY AND EFFICACY IN PHASE 1B CLINICAL TRIAL IN COLD AGGLUTININ DISEASE (CAGD) PATIENTS

Dec 11 2017

BRIEF-Bioverativ reports Q3 earnings per share $0.63

* Q3 revenue $291.6 million versus i/b/e/s view $285.5 million

Oct 26 2017

BRIEF-Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400

* Sangamo and Bioverativ announce FDA acceptance of IND application for ST-400 -- a gene-edited cell therapy candidate -- to treat beta-thalassemia

Oct 02 2017

BRIEF-Bioverativ and Bicycle Therapeutics enter into strategic research collaboration

* Bioverativ and Bicycle Therapeutics enter into strategic research collaboration to develop therapies for haemophilia and sickle cell disease

Sep 06 2017

BRIEF-Bioverativ reports Q2 GAAP earnings per share $0.71

* Q2 earnings per share view $0.71 -- Thomson Reuters I/B/E/S

Aug 02 2017

BRIEF-Valueact Capital Management LLC reports 3.8 pct stake in Bioverativ Inc as of July 13 - SEC filing

* Valueact Capital Management LLC reports 3.8 percent stake in Bioverativ Inc as of July 13 versus 7.5 percent stake as of Feb 28 - SEC filing Source text:(http://bit.ly/2u29MGC) Further company coverage:

Jul 17 2017

BRIEF-Bioverativ says on June 28, entered into a credit agreement

* Bioverativ inc - on june 28, entered into a credit agreement by and among bioverativ and certain subsidiaries as borrowers - sec filing

Jun 29 2017

Earnings vs. Estimates